...
search icon
acrv-img

Acrivon Therapeutics, Inc. Common Stock Share Price

ACRV
NMQ
$1.63
+$0.05
(3.16%)
1D
Industry: Biotechnology Sector: Health Care

Acrivon Therapeutics, Inc. Common Stock Analyst Forecast

Acrivon Therapeutics, Inc. Common Stock Share Price Chart

Acrivon Therapeutics, Inc. Common Stock Key Stock Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$49.86M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
433.75K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
1.76
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$1.05 L
$6.08 H
$1.63

About Acrivon Therapeutics, Inc. Common Stock, Common Stock

Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers and develops oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its generative phosphoproteomics platform. The company operates Acrivon Predictive Precision Proteomics (AP3), a precision medicine platform that enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2 for the treatment of patients with endometrial and platinum-resistant ovarian cancer, and SCCs, such as SCCHN and anal cancer. The company is also developing ACR-2316, a dual WEE1 and PKMYT1 inhibitor small molecule candidate; and a preclinical stage AP3-and co-crystallography-based preclinical cell cycle program. Acrivon Therapeutics, Inc. was incorporated in 2018 and is based in Watertown, Massachusetts. more

Industry: BiotechnologySector: Health Care

Acrivon Therapeutics, Inc. Common Stock Stock Returns

Time FrameACRVSectorS&P500
1-Week Return-5.39%-1.08%-1.38%
1-Month Return-7.06%-0.47%-1.81%
3-Month Return-23.67%2.13%1.38%
6-Month Return20.61%17.04%5.68%
1-Year Return-70.52%6.56%11.74%
3-Year Return-93.1%16.78%65.15%
5-Year Return-90.5%34.34%73.68%

Acrivon Therapeutics, Inc. Common Stock Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Cost of Revenue13.00K832.00K1.09M536.00K1.01M[{"date":"2020-12-31","value":1.19,"profit":true},{"date":"2021-12-31","value":75.98,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":48.95,"profit":true},{"date":"2024-12-31","value":91.87,"profit":true}]
Gross Profit(13.00K)(832.00K)(1.09M)(536.00K)(1.01M)[{"date":"2020-12-31","value":-1300000,"profit":false},{"date":"2021-12-31","value":-83200000,"profit":false},{"date":"2022-12-31","value":-109500000,"profit":false},{"date":"2023-12-31","value":-53600000,"profit":false},{"date":"2024-12-31","value":-100600000,"profit":false}]
Gross Margin-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Operating Expenses3.17M16.18M32.66M66.70M88.19M[{"date":"2020-12-31","value":3.59,"profit":true},{"date":"2021-12-31","value":18.35,"profit":true},{"date":"2022-12-31","value":37.03,"profit":true},{"date":"2023-12-31","value":75.63,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Operating Income(3.17M)(16.18M)(32.66M)(67.24M)(89.20M)[{"date":"2020-12-31","value":-316800000,"profit":false},{"date":"2021-12-31","value":-1618400000,"profit":false},{"date":"2022-12-31","value":-3265700000,"profit":false},{"date":"2023-12-31","value":-6723700000,"profit":false},{"date":"2024-12-31","value":-8919900000,"profit":false}]
Total Non-Operating Income/Expense---13.89M17.84M[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":77.82,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Pre-Tax Income(5.31M)(16.24M)(31.17M)(60.39M)(80.56M)[{"date":"2020-12-31","value":-530600000,"profit":false},{"date":"2021-12-31","value":-1624300000,"profit":false},{"date":"2022-12-31","value":-3116700000,"profit":false},{"date":"2023-12-31","value":-6038800000,"profit":false},{"date":"2024-12-31","value":-8055600000,"profit":false}]
Income Taxes(193.30K)(199.56K)(1.49M)1.00-[{"date":"2020-12-31","value":-19329700,"profit":false},{"date":"2021-12-31","value":-19955800,"profit":false},{"date":"2022-12-31","value":-149000000,"profit":false},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Income After Taxes---(60.39M)-[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":-6038800100,"profit":false},{"date":"2024-12-31","value":"-","profit":true}]
Income From Continuous Operations(5.31M)(16.24M)(31.17M)(50.06M)(80.56M)[{"date":"2020-12-31","value":-530600000,"profit":false},{"date":"2021-12-31","value":-1624300000,"profit":false},{"date":"2022-12-31","value":-3116700000,"profit":false},{"date":"2023-12-31","value":-5006500000,"profit":false},{"date":"2024-12-31","value":-8055600000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income(5.31M)(16.24M)(29.68M)(60.39M)(80.56M)[{"date":"2020-12-31","value":-530600000,"profit":false},{"date":"2021-12-31","value":-1624300000,"profit":false},{"date":"2022-12-31","value":-2967700000,"profit":false},{"date":"2023-12-31","value":-6038800000,"profit":false},{"date":"2024-12-31","value":-8055600000,"profit":false}]
EPS (Diluted)--(1.31)(2.73)(2.44)[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":-131,"profit":false},{"date":"2023-12-31","value":-273,"profit":false},{"date":"2024-12-31","value":-244,"profit":false}]

Acrivon Therapeutics, Inc. Common Stock Ratios

Acrivon Therapeutics, Inc. Common Stock Liquidity Ratios

These ratios help you determine the liquidity of the company. Higher is better.

ACRV
Cash Ratio 8.68
Current Ratio 8.75

Acrivon Therapeutics, Inc. Common Stock Asset Efficiency Ratios

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

ACRV
ROA (LTM) -30.89%
ROE (LTM) -50.23%

Acrivon Therapeutics, Inc. Common Stock Liability Ratios

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

ACRV
Debt Ratio Lower is generally better. Negative is bad. 0.11
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.89

Acrivon Therapeutics, Inc. Common Stock Valuation Ratios

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

ACRV
Trailing PE NM
Forward PE NM
P/S (TTM) 0.00
P/B 0.39
Price/FCF NM
EV/R 0.00
EV/Ebitda NM

FAQs

What is Acrivon Therapeutics, Inc. Common Stock share price today?

Acrivon Therapeutics, Inc. Common Stock (ACRV) share price today is $1.63

Can Indians buy Acrivon Therapeutics, Inc. Common Stock shares?

Yes, Indians can buy shares of Acrivon Therapeutics, Inc. Common Stock (ACRV) on Vested. To buy

from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in ACRV stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Acrivon Therapeutics, Inc. Common Stock be purchased?

Yes, you can purchase fractional shares of Acrivon Therapeutics, Inc. Common Stock (ACRV) via the Vested app. You can start investing in Acrivon Therapeutics, Inc. Common Stock (ACRV) with a minimum investment of $1.

How to invest in Acrivon Therapeutics, Inc. Common Stock shares from India?

You can invest in shares of Acrivon Therapeutics, Inc. Common Stock (ACRV) via Vested in three simple steps:

  • Click on Sign Up or Invest in ACRV stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Acrivon Therapeutics, Inc. Common Stock shares
What is Acrivon Therapeutics, Inc. Common Stock 52-week high and low stock price?

The 52-week high price of Acrivon Therapeutics, Inc. Common Stock (ACRV) is $6.08. The 52-week low price of Acrivon Therapeutics, Inc. Common Stock (ACRV) is $1.05.

What is Acrivon Therapeutics, Inc. Common Stock price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Acrivon Therapeutics, Inc. Common Stock (ACRV) is

What is Acrivon Therapeutics, Inc. Common Stock price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Acrivon Therapeutics, Inc. Common Stock (ACRV) is 0.39

What is Acrivon Therapeutics, Inc. Common Stock dividend yield?

The dividend yield of Acrivon Therapeutics, Inc. Common Stock (ACRV) is 0.00%

What is the Market Cap of Acrivon Therapeutics, Inc. Common Stock?

The market capitalization of Acrivon Therapeutics, Inc. Common Stock (ACRV) is $49.86M

What is Acrivon Therapeutics, Inc. Common Stock's stock symbol?

The stock symbol (or ticker) of Acrivon Therapeutics, Inc. Common Stock is ACRV

How Can Investors Use Acrivon Therapeutics, Inc. Common Stock Share Price Data for Long-Term Investment Decisions?

Consider the share price of Acrivon Therapeutics, Inc. Common Stock as a long-term story and not a daily point list. The price represents a movement of the stock in both good and bad times when looked at over many years. This assists the investors to know whether Acrivon Therapeutics, Inc. Common Stock has succeeded to expand steadily and overcome market declines. With this price movement observed and the way the business is progressing, it is easier to make a decision whether the stock is worth having in the long term or not.

How does USD - INR currency movement impact returns from Acrivon Therapeutics, Inc. Common Stock shares for Indian investors?

When investing in Acrivon Therapeutics, Inc. Common Stock shares, you are not based in India then your investment is not just based on the stock price. It is also determined by the currency movement of the dollar in relation to the rupee. When you have an appreciation of the Acrivon Therapeutics, Inc. Common Stock stock and the dollar appreciation is also the same, you gain more in terms of rupees. When the rupee appreciated, it will lower your profits. This currency flow is a silent cause of great contribution to your ultimate returns over many years.

How should investors compare Acrivon Therapeutics, Inc. Common Stock share price with other stocks in the same sector?

Rather than merely checking the share price of Acrivon Therapeutics, Inc. Common Stock and comparing it with that of other stocks in the same sector, one can check how robust the business is. Investors tend to compare such aspects as profits, cash generation, and the stability of the revenues of the company. This means that Acrivon Therapeutics, Inc. Common Stock stock in most cases does not react in the same manner as other companies in the sector due to its brand and services revenue.

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top